Seymour, Rachel B.
Wally, Meghan K.
Hsu, Joseph R.
Beuhler, Michael
Bosse, Michael J.
Gibbs, Michael
Griggs, Christopher
Jarrett, Steven
Leas, Daniel
Odum, Susan
Roomian, Tamar
Runyon, Michael
Saha, Animita
Schiro, Sharon
Sullivan, D. Matthew
Watling, Brad
Wyatt, Stephen
Yu, Ziqing
,
Funding for this research was provided by:
Centers for Disease Control and Prevention (CE14-004 CE002520; R01 CE003001, CE14-004 CE002520; R01 CE003001, CE14-004 CE002520; R01 CE003001, CE14-004 CE002520; R01 CE003001)
Article History
Received: 30 September 2022
Accepted: 29 September 2023
First Online: 20 October 2023
Declarations
:
: This study was approved by the Atrium Health Institutional Review Board and included approval of waiver of informed consent. This study was performed in accordance with relevant guidelines and regulations.
: Not applicable.
: Dr. Hsu reports consultancy and speaker fees for Stryker, consultancy and speaker fees from Smith & Nephew speakers’ bureau, speaker fees from Integra Lifesciences, and speaker fees from Depuy/Synthes. Dr. Bosse reports stock ownership in an orthopaedic implant company and grant funding from the Department of Defense. Dr. Griggs reports board membership for the American College of Emergency Physicians and payment from Boston University for preparation of pain management and opioid prescribing educational materials. Dr. Runyon reports research grant funding from Abbot Laboratories and Bristol-Myers Squibb and royalties/licenses from UpToDate. All remaining authors do not have any competing interests to declare.